Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claes Held

Showing results (191-200 of 227) with videos related to

Pageof 23
Sort By:
JAMA Cardiology|July 21, 2016
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary SyndromePaul L Hess, Daniel M Wojdyla, Sana M Al-Khatib, et al.
Circulation|June 23, 2025
Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II SubstudyPernille G Thrane, Michael Maeng, Akiko Maehara, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
Journal of the American College of Cardiology|August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary DiseaseDaniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|April 4, 2024
Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two yearsElmir Omerovic, Stefan James, Truls Råmundal, et al.
Circulation|December 16, 2022
Coronary Artery Lesion Lipid Content and Plaque Burden in Diabetic and Nondiabetic Patients: PROSPECT IIChristine Gyldenkerne, Michael Maeng, Lars Kjøller-Hansen, et al.
Lancet (London, England)|March 14, 2021
Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history studyDavid Erlinge, Akiko Maehara, Ori Ben-Yehuda, et al.
JACC. Cardiovascular Imaging|February 25, 2025
Association Between Physiological Significance and Vulnerable Plaque Characteristics in Patients With Myocardial Infarction: A Prospect II SubstudyKetina Arslani, Thomas Engstrøm, Michael Maeng, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
Circulation|December 28, 2018
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 TrialsAlexander C Fanaroff, Robert Clare, Karen S Pieper, et al.
Pageof 23

Showing results (191-200 of 227) with videos related to

Sort By:
Pageof 23
JAMA Cardiology|July 21, 2016
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary SyndromePaul L Hess, Daniel M Wojdyla, Sana M Al-Khatib, et al.
Circulation|June 23, 2025
Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II SubstudyPernille G Thrane, Michael Maeng, Akiko Maehara, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
Journal of the American College of Cardiology|August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary DiseaseDaniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|April 4, 2024
Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two yearsElmir Omerovic, Stefan James, Truls Råmundal, et al.
Circulation|December 16, 2022
Coronary Artery Lesion Lipid Content and Plaque Burden in Diabetic and Nondiabetic Patients: PROSPECT IIChristine Gyldenkerne, Michael Maeng, Lars Kjøller-Hansen, et al.
Lancet (London, England)|March 14, 2021
Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history studyDavid Erlinge, Akiko Maehara, Ori Ben-Yehuda, et al.
JACC. Cardiovascular Imaging|February 25, 2025
Association Between Physiological Significance and Vulnerable Plaque Characteristics in Patients With Myocardial Infarction: A Prospect II SubstudyKetina Arslani, Thomas Engstrøm, Michael Maeng, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
Circulation|December 28, 2018
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 TrialsAlexander C Fanaroff, Robert Clare, Karen S Pieper, et al.
Pageof 23